Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection
- 9 June 2022
- journal article
- research article
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 192 (2) , 731-739
Abstract
Purpose To evaluate IgG production in a group of vaccinated and unvaccinated subjects previously infected, or not, with SARS-CoV-2. Methods A total of 316 subjects were enrolled at different times after vaccination and/or infection. IgG against target S1 subunit of the spike protein of SARS-COV-2 was assessed by a chemiluminescent microparticle immunoassay. Participant data was collected using a clinical-epidemiological survey. Results A total of 56.2% (n = 146) of our cohort was vaccinated, with 27.5% (n = 36) reporting a previous infection. Of these, all were IgG positive at the time of the study, regardless of gender, age category, vaccine type, and elapsed time since vaccination. The vaccinated group without a previous infection (72.5%, n = 95) showed a slightly lower IgG seropositivity and median values, overall, although significantly higher in females and lower with the ChAdOx1 nCoV-19 (AstraZeneca) vaccine. Vaccinated subjects above the age of 65 showed a trend towards higher median IgG values (13,911.0 AU/mL), when previously infected with SARS-CoV-2, but comparatively lower IgG median value (5158.7 AU/mL) in its absence. In all vaccinated groups, IgG antibody production increased at 1–2 weeks, peaking at 4–6 weeks. Afterward, IgG decreased progressively but almost all subjects (97.7%, n = 128) were seropositive for the remainder of our study. Fully vaccinated individuals with a past infection showed a lower IgG rate of decrease versus their uninfected counterparts (17.9 vs 22.6%, respectively). Conclusion Our findings suggest a higher effect of vaccination on the production IgG antibodies, as opposed to natural infection. Nonetheless, in general, antibody titers waned rapidly.Keywords
This publication has 39 references indexed in Scilit:
- T‐cell responses and therapies against SARS‐CoV‐2 infectionImmunology, 2020
- COVID-19 in children and young peopleThe Lancet Rheumatology, 2020
- Molecular biology of coronaviruses: current knowledgeHeliyon, 2020
- The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfectionJournal of General Virology, 2020
- Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2Cell, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Subunit Vaccines Against Emerging Pathogenic Human CoronavirusesFrontiers in Microbiology, 2020
- Factors That Influence the Immune Response to VaccinationClinical Microbiology Reviews, 2019
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significanceRespirology, 2006